Abstract
Abstract
Objective
To assess the cost-effectiveness of using cheaper-but-noisier outcome measures, such as a short questionnaire, for large simple clinical trials.
Background
To detect associations reliably, trials must avoid bias and random error. To reduce random error, we can increase the size of the trial and increase the accuracy of the outcome measurement process. However, with fixed resources, there is a trade-off between the number of participants a trial can enrol and the amount of information that can be collected on each participant during data collection.
Methods
To consider the effect on measurement error of using outcome scales with varying numbers of categories, we define and calculate the variance from categorisation that would be expected from using a category midpoint; define the analytic conditions under which such a measure is cost-effective; use meta-regression to estimate the impact of participant burden, defined as questionnaire length, on response rates; and develop an interactive web-app to allow researchers to explore the cost-effectiveness of using such a measure under plausible assumptions.
Results
An outcome scale with only a few categories greatly reduced the variance of non-measurement. For example, a scale with five categories reduced the variance of non-measurement by 96% for a uniform distribution. We show that a simple measure will be more cost-effective than a gold-standard measure if the relative increase in variance due to using it is less than the relative increase in cost from the gold standard, assuming it does not introduce bias in the measurement. We found an inverse power law relationship between participant burden and response rates such that a doubling the burden on participants reduces the response rate by around one third. Finally, we created an interactive web-app (https://benjiwoolf.shinyapps.io/cheapbutnoisymeasures/) to allow exploration of when using a cheap-but-noisy measure will be more cost-effective using realistic parameters.
Conclusion
Cheaper-but-noisier questionnaires containing just a few questions can be a cost-effective way of maximising power. However, their use requires a judgement on the trade-off between the potential increase in risk of information bias and the reduction in the potential of selection bias due to the expected higher response rates.
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Statista. Subjects per clinical trial started worldwide by phase 2015–2020. [cited 2024 Jul 19]. Available from: https://www.statista.com/statistics/1249080/average-number-subjects-per-trial-started-by-phase-worldwide/.
2. Califf RM. Large simple trials: really, it can’t be that simple! Eur Heart J. 2014;35(9):549–51.
3. Roundtable on Value and Science-Driven Health Care, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine. Large simple trials and knowledge generation in a learning health system: workshop summary. Washington (DC): National Academies Press (US); 2013 [cited 2024 Jul 19]. (The National Academies Collection: Reports funded by National Institutes of Health). Available from: http://www.ncbi.nlm.nih.gov/books/NBK201274/.
4. Peto R. Why do we need systematic overviews of randomized trials? Statist Med. 1987;6(3):233–40.
5. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3(4):409–22.